Form 4 for NVCR NovoCure Ltd
Accepted 2021-11-29 00:00:00 ET · period of report 2021-11-26 · accession 0001645113-21-000116 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2021-11-29 | 2021-11-26 | NVCR | Danziger Asaf | CEO, Dir | P - Purchase | $102.44 | +4,974 | 13.3K | +60% | +$509.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2021-11-26 | P | A | 1,000 | $103.37 | 13,172 | D | — | — | |
| 2 | Common | Ordinary Shares | 2021-11-26 | P | A | 3,870 | $102.36 | 12,172 | D | — | — | (F1) On November 26, 2021, Mr. Danziger purchased 3,870 shares in multiple trades at prices ranging from $102.00 to $102.60. The price reported above reflects the weighted average purchase price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. |
| 3 | Common | Ordinary Shares | 2021-11-26 | P | A | 104 | $96.50 | 13,276 | D | — | — |